GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Axsome Therapeutics
Axsome Therapeutics is a biopharmaceutical company focused on diseases of the central nervous system. Its stock price is driven by news of the commercial launch of its drugs and clinical trial results. The chart is a story of expectations and reality in the complex pharmaceutical sector.
Share prices of companies in the market segment - Neuro
Axsome Therapeutics is a biopharmaceutical company focused on treating diseases of the central nervous system. We classify it in the Neuro sector. The chart below shows the overall performance of this biotech segment, not just Axsome shares.
Broad Market Index - GURU.Markets
Axsome Therapeutics is a biopharmaceutical company focused on developing drugs to treat central nervous system disorders, such as depression and migraines. A major player in neuroscience, it is included in the GURU.Markets index. The chart below shows the overall market trend. See how Axsome shares correlate with sentiment in the healthcare sector.
Change in the price of a company, segment, and market as a whole per day
AXSM - Daily change in the company's share price Axsome Therapeutics
Change_Co for Axsome Therapeutics (AXSM), a biopharmaceutical company specializing in neurological diseases, reflects its sensitivity to FDA approvals and the commercialization of its products. AXSM's volatility is a measure of exposure to clinical and regulatory news. This metric is essential for formulaic modeling of risks and potential in neuropharmacology.
Daily change in the price of a set of shares in a market segment - Neuro
Axsome Therapeutics, Inc. is a biotech company. This chart highlights the sector's extreme volatility. Comparing it to AXSM, which focuses on CNS diseases, helps assess its risk compared to more diversified pharmaceutical companies.
Daily change in the price of a broad market stock, index - GURU.Markets
Axsome Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of diseases of the central nervous system. Neuroscience is a risky field of research. The chart below illustrates the high volatility typical of the biotech sector.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Axsome Therapeutics
Axsome is a biotech company with a successful pipeline of neuroscience drugs. Its year-over-year performance reflects both the commercial success of its existing drugs and investor confidence in its R&D platform, which is focused on new breakthrough products.
Annual dynamics of market capitalization of the market segment - Neuro
Axsome Therapeutics, Inc. is a biopharmaceutical company focused on developing drugs for the treatment of central nervous system disorders. Its success depends on the results of clinical trials and the commercialization of its products. The chart below shows how the market views its scientific potential and the competition.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Axsome Therapeutics, bringing new drugs to market for the treatment of central nervous system disorders, lives to the rhythm of the pharmaceutical industry. Its stock price is driven by sales success and research progress, not economic cycles. The company's chart tells the story of how medical innovation creates its own growth vector, independent of the market.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Axsome Therapeutics
The value of Axsome Therapeutics, a biopharmaceutical company, depends on the commercial and clinical success of its drugs. The monthly fluctuations on the chart reflect sales data for approved drugs for depression and migraine, as well as news on the progress of trials for other candidates in its neuroscience pipeline.
Monthly dynamics of market capitalization of the market segment - Neuro
This chart reflects the dynamics of the biotech sector. For Axsome, a company focused on the central nervous system, it's the backdrop. Its movements demonstrate how the successful launch of a new drug and progress in clinical trials of other candidates allow it to outperform expectations in a volatile sector.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Axsome Therapeutics is a biopharmaceutical company specializing in developing drugs to treat central nervous system (CNS) disorders, such as depression and migraine. The chart below shows general market trends. How does Axsome, whose fate depends on FDA approvals, compare?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Axsome Therapeutics
Axsome Therapeutics shares respond weekly to the slightest news in the world of neurology and psychiatry. Their price is a barometer of investor hopes for the approval of new drugs for depression and migraines. This chart shows how sensitive the market is to every step the company takes toward new therapeutic solutions.
Weekly dynamics of market capitalization of the market segment - Neuro
Axsome Therapeutics shares, like other neuroscience companies, react weekly to industry-wide news. Investor sentiment toward the entire industry can shift due to drug pricing policies or a competitor's breakthrough. This chart compares Axsome's pulse with the overall pharmaceutical sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Axsome Therapeutics operates in a sector where a single drug approval can override any macroeconomic data. This chart allows you to assess how often the company's shares move counter to the overall market trend. Are its weekly ups and downs the result of its own events, or is it susceptible to market-wide panic?
Market capitalization of the company, segment and market as a whole
AXSM - Market capitalization of the company Axsome Therapeutics
The chart below maps Axsome Therapeutics' journey through the world of CNS drug development. Its market capitalization dynamics clearly demonstrate investors' reactions to key events, such as new drug approvals and trial results. It's a visual history of the market's faith in the company's innovative potential.
AXSM - Share of the company's market capitalization Axsome Therapeutics within the market segment - Neuro
Axsome Therapeutics is fighting for a share of the highly competitive CNS drug sector. The company's share of the segment's total market capitalization is a barometer of its commercial success and investor confidence in its future drugs. The chart below illustrates how each successful launch or new study allows Axsome to gain ground against neuroscience giants.
Market capitalization of the market segment - Neuro
Axsome Therapeutics develops drugs for the treatment of central nervous system disorders. To appreciate its potential, one must understand the size of the overall market. The chart below is a barometer of the neuroscience sector. Its growth reflects how investors perceive the need for new treatments for depression and migraines, creating enormous room for growth.
Market capitalization of all companies included in a broad market index - GURU.Markets
The Axsome Therapeutics market capitalization chart is a financial trajectory for central nervous system drug development. Its volatility reflects how the market evaluates risks and potential breakthroughs in depression and migraine treatments. The dynamics below visually reflect the journey from the lab to the pharmacy, where every piece of news changes everything.
Book value capitalization of the company, segment and market as a whole
AXSM - Book value capitalization of the company Axsome Therapeutics
Axsome Therapeutics' core value lies in its intellectual property development of drugs for the treatment of central nervous system diseases. Book value reflects the material side of this process: the cost of laboratories and research equipment. The chart below demonstrates how the company has invested in its physical foundation to achieve scientific breakthroughs.
AXSM - Share of the company's book capitalization Axsome Therapeutics within the market segment - Neuro
Axsome Therapeutics' strength lies in its research and development infrastructure, built to combat CNS diseases. These specialized laboratories and clinical centers provide the physical foundation for developing innovative drugs. Below, you'll see the company's share of the sector's tangible assets dedicated to brain health.
Market segment balance sheet capitalization - Neuro
Axsome Therapeutics is a biotech company whose value lies in its development portfolio and patents, not its production capacity. It's a classic example of a capital-light business. The chart below reflects the book value of the entire pharmaceutical sector, highlighting its R&D-focused model.
Book value of all companies included in the broad market index - GURU.Markets
Axsome Therapeutics' balance sheet is a capital asset for fighting CNS diseases. The company's relatively small share of total market assets reflects the concentrated strength of its R&D investments. The chart allows one to assess the material resources behind the development of innovative drugs aimed at solving complex medical problems.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Axsome Therapeutics
Axsome Therapeutics has modest tangible assets, but its market valuation reflects the enormous expectations for its CNS drugs. The P/B ratio here is a barometer of market confidence. It shows how many times higher investors value the potential of a single successful blockbuster than all the company's labs and equipment.
Market to book capitalization ratio in a market segment - Neuro
Axsome Therapeutics develops drugs for the central nervous system. This chart shows the premium investors are willing to pay over the value of the company's physical assets. This premium reflects the market's confidence in the potential success of Axsome's drugs and the future cash flows from their sales.
Market to book capitalization ratio for the market as a whole
Axsome Therapeutics is a biopharmaceutical company focused on treating diseases of the central nervous system. This chart reflects the average market valuation of the business. Against this backdrop, Axsome's high premium reflects how investors value the potential of its drug candidates, not its current tangible assets.
Debts of the company, segment and market as a whole
AXSM - Company debts Axsome Therapeutics
For Axsome Therapeutics, which focuses on CNS diseases, debt is a strategic acceleration tool. Borrowed funds enable the company to finance costly clinical trials and the commercialization of new drugs. This chart illustrates how the company balances the need to invest in breakthrough treatments with maintaining financial stability.
Market segment debts - Neuro
Axsome Therapeutics specializes in drugs for the treatment of central nervous system disorders. Developing new drugs is a capital-intensive process with unpredictable outcomes. Therefore, its leverage is an indicator of management's confidence in the success of its research. This chart reflects the degree of risk the company is willing to take on for the sake of future breakthroughs.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Axsome Therapeutics
Axsome Therapeutics specializes in central nervous system drugs, an area characterized by lengthy and expensive clinical trials. The chart below provides investors with an understanding of how the company balances equity and debt financing to advance its development. The debt level here is an indicator of the financial burden on the path to commercialization.
Market segment debt to market segment book capitalization - Neuro
Axsome Therapeutics specializes in drugs for the treatment of central nervous system disorders. Developing such drugs is a lengthy and capital-intensive process. This chart shows the overall debt position of the entire neurological pharmaceutical segment, allowing one to assess how Axsome's fundraising strategy fits within the industry context.
Debt to book value of all companies in the market
Axsome Therapeutics develops CNS drugs, which requires significant long-term investment. This chart shows the overall market leverage, serving as an indicator of corporate confidence. Against this backdrop, it's possible to assess how Axsome's capital-dependent financial strategy aligns with the overall sentiment of investors and creditors in the economy.
P/E of the company, segment and market as a whole
P/E - Axsome Therapeutics
Axsome Therapeutics is developing new treatments for diseases of the central nervous system. A high value on this chart for a biotech company often indicates high investor expectations for future sales of its drugs. The valuation depends on the success of clinical trials, not on current profits, which may not be forthcoming.
P/E of the market segment - Neuro
Neuroscience companies like Axsome Therapeutics often lack consistent profitability, but they possess enormous potential. This chart shows the average market valuation for more mature competitors. This allows investors to understand the premium the market is willing to pay for future growth in this complex and risky pharmaceutical field.
P/E of the market as a whole
Axsome Therapeutics specializes in developing drugs for the treatment of central nervous system diseases. Like many biopharmaceutical companies, its valuation is a bet on the future success of clinical trials. This indicator of overall market sentiment serves only as a backdrop, while Axsome's fate is decided in the regulatory chambers and by trial data, not on Wall Street.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Axsome Therapeutics
Axsome Therapeutics specializes in drugs for the treatment of central nervous system disorders. This chart illustrates analysts' expectations regarding the commercial success of its drug portfolio. It answers the question: do experts believe future sales will justify the current share price and generate stable cash flow?
%20P%2FE%20Axsome%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Axsome-Therapeutics&v=1772567568468 "Chart of the company's future (projected) P/E Axsome Therapeutics")
Future (projected) P/E of the market segment - Neuro
Axsome Therapeutics develops drugs for the treatment of central nervous system diseases, an area with a high need for innovation. This chart shows how analysts estimate the company's future revenue compared to other players in the neuroscience sector. This reflects the market's confidence in the success of its clinical developments and future commercial potential.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772567568620 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
Axsome Therapeutics focuses on drugs for the treatment of central nervous system disorders. This chart is an indicator of overall market risk appetite. For Axsome, whose success depends on clinical trial results and regulatory approvals, positive market expectations create a favorable funding environment and support a high valuation in anticipation of a breakthrough.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772567568674 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Axsome Therapeutics
Axsome Therapeutics specializes in treating central nervous system disorders, bringing new drugs to market to combat depression and migraines. The dynamics on this chart show how successfully the company is commercializing its developments. Each spike or dip tells a story about sales, clinical trial results, and competition in the pharmaceutical industry.
Profit of companies in the market segment - Neuro
Axsome Therapeutics focuses on developing innovative treatments for central nervous system disorders, such as depression and migraine. This is a market with huge needs and high barriers to entry. This chart illustrates the overall financial dynamics of the neuroscience sector, showing whether new drugs are finding traction and commercial success.
Overall market profit
Axsome Therapeutics develops new treatments for diseases of the central nervous system. The company's profit dynamics are more closely tied to successful drug trials than to the overall economy. However, the financial health of corporations, as shown here, indirectly impacts Axsome: it determines the solvency of healthcare systems and the willingness of investors to finance risky projects.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Axsome Therapeutics
Axsome Therapeutics specializes in the treatment of central nervous system diseases, where the need for new therapeutics is enormous. The company's prospects are inextricably linked to the approval and commercial success of its drugs. This figure reflects market expectations for future revenue, which are directly dependent on regulatory decisions and the acceptance of the drugs by the medical community.
%20profit%20of%20the%20company%20Axsome%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Axsome-Therapeutics&v=1772567568973 "Graph of future (projected) profit of the company Axsome Therapeutics")
Future (predicted) profit of companies in the market segment - Neuro
Axsome Therapeutics specializes in treating central nervous system disorders such as depression and migraines—markets with enormous potential. The dynamics of this chart reflect general expectations for the biotech industry, but Axsome's breakthrough neuroscience drugs are particularly likely to enable the company to significantly exceed industry average profitability projections in the future.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772567569031 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
Axsome Therapeutics specializes in treating diseases of the central nervous system. The dynamics in this chart are important for the company in two ways. On the one hand, demand for its drugs is only slightly dependent on the health of the economy. On the other hand, overall profit forecasts influence the cost of capital and M&A activity, which are critical for growth in the biotech sector.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772567569122 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Axsome Therapeutics
Axsome Therapeutics specializes in treating central nervous system diseases, bringing new drugs to market. This metric demonstrates the premium investors are willing to pay for the company's revenue. Its growth is often associated with successful clinical trials and the anticipation of approval for new drugs that could become blockbusters.
P/S market segment - Neuro
Axsome Therapeutics focuses on treating diseases of the central nervous system. For a biopharmaceutical company, market valuation often outpaces actual revenue, reflecting expectations for future drugs. This chart shows how investors value companies in the sector on average, helping determine whether they see greater potential in Axsome's portfolio than their peers.
P/S of the market as a whole
Axsome Therapeutics is developing new treatments for diseases of the central nervous system. For a biopharmaceutical company whose success depends on research results, revenue is volatile. This indicator reflects the overall market valuation of revenue and helps understand whether Axsome's stock price reflects a premium for future potential compared to the average company.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Axsome Therapeutics
Axsome Therapeutics specializes in drugs for the treatment of central nervous system diseases. This chart shows how the market values the company's future sales, which are directly dependent on the successful commercialization of already approved drugs and progress in developing new therapeutic candidates, a key aspect of biopharmaceuticals.
%20P%2FS%20Axsome%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Axsome-Therapeutics&v=1772567569408 "The graph of the company's future (projected) P/S Axsome Therapeutics")
Future (projected) P/S of the market segment - Neuro
Axsome Therapeutics focuses on central nervous system disorders, bringing new treatments for depression and migraines to market. The graph below compares the company's estimated future sales with its industry. It illustrates how highly the market values the commercial potential of Axsome's drugs and its ability to capture market share.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772567569463 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
Axsome Therapeutics focuses on developing drugs to treat diseases of the central nervous system, where there is a huge unmet need. The optimism demonstrated by this indicator is often fueled by medical breakthroughs. Each successful drug from Axsome has the potential to generate billions of dollars in revenue, confirming investors' faith in the potential of the biotech sector.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772567569590 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Axsome Therapeutics
Axsome Therapeutics focuses on treating diseases of the central nervous system. The dynamics in this chart directly reflect the commercial success of its drugs, particularly those for the treatment of depression. Growth in this indicator indicates increased sales and recognition of the company's products by both doctors and patients, forming the basis for further development.
Sales of companies in the market segment - Neuro
Axsome Therapeutics specializes in treating central nervous system disorders, bringing innovative drugs to market. The success of their developments, such as depression medications, directly impacts the growth of the neuroscience segment. This chart shows how the commercialization of one company's breakthrough therapies drives revenue growth for the entire pharmaceutical industry.
Overall market sales
Axsome Therapeutics, which specializes in central nervous system medications, is sensitive to consumer confidence, as reflected in aggregate sales trends. Patients' ability to afford new treatments and insurers' willingness to cover them are directly linked to the overall health of the economy, making this chart an important indicator of potential demand.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Axsome Therapeutics
Axsome Therapeutics specializes in drugs for the treatment of central nervous system disorders. Its revenue forecast reflects Wall Street's expectations for the market penetration of its new drugs. This data reflects the company's anticipated prescription volume and its ability to compete with leading companies in the treatment of depression, migraines, and other neurological conditions.
%20sales%20of%20the%20company%20Axsome%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Axsome-Therapeutics&v=1772567570099 "Schedule of future (projected) sales of the company Axsome Therapeutics")
Future (projected) sales of companies in the market segment - Neuro
Axsome Therapeutics specializes in treating central nervous system disorders, offering innovative solutions for complex conditions such as depression. This chart illustrates future expectations for the entire neurobiological drug sector. It helps understand whether Axsome's portfolio can drive growth amid overall industry trends.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772567570192 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
The forecasts in this chart directly impact Axsome Therapeutics, a developer of CNS drugs. An improved overall economic environment and rising consumer spending mean greater access to healthcare and a willingness of healthcare systems to invest in new, more effective treatments. For Axsome, this translates into potential growth in demand for their therapies.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772567570519 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Axsome Therapeutics
Axsome Therapeutics develops innovative treatments for diseases of the central nervous system. For a biotech company at the market launch stage, this graph is key. It demonstrates how successfully the commercialization of new drugs begins to recoup years of research investment, turning scientific advances into financial returns.
Market segment marginality - Neuro
Axsome Therapeutics specializes in developing innovative treatments for central nervous system disorders, such as depression and migraine. This chart shows the company's operating margin relative to its pharmaceutical industry peers. Above-average performance may indicate successful commercial drug launches and effective intellectual property management.
Market marginality as a whole
Axsome Therapeutics is tackling the most complex diseases of the nervous system. This chart shows the average hospital temperature for the entire business, but for Axsome, it's a big-ticket game. The success of a single drug can skyrocket their profitability, demonstrating how medical innovation can outpace any market average.
Employees in the company, segment and market as a whole
Number of employees in the company Axsome Therapeutics
Axsome Therapeutics focuses on treating diseases of the central nervous system, and this chart reflects its journey from research to commercialization. Staff growth, particularly in sales and marketing, is a key indicator of successful drug launches and the development of an infrastructure to promote them to physicians and patients.
Share of the company's employees Axsome Therapeutics within the market segment - Neuro
Axsome Therapeutics is tackling the most complex diseases of the nervous system. This metric measures the company's intellectual power, not its financial strength—the proportion of neuroscience specialists it brings together. It demonstrates the human resources Axsome devotes to research, reflecting its contribution and influence as an employer in this knowledge-intensive field.
Number of employees in the market segment - Neuro
Axsome Therapeutics specializes in treating diseases of the central nervous system. The company's key resource is its highly qualified scientists and clinicians. This chart illustrates how the company is building a team to advance its drugs through the complex stages of clinical trials and market launch, reflecting the growth and development phase of its portfolio.
Number of employees in the market as a whole
Axsome Therapeutics specializes in treating diseases of the central nervous system, and its success is determined by the results of clinical trials. While this graph illustrates the general ebb and flow of the labor market, the staffing dynamics at Axsome are an indicator of progress in medicine, where every new employee can bring a life-saving drug closer to fruition.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Axsome Therapeutics (AXSM)
Axsome Therapeutics, a biopharmaceutical company, has a small staff, but its value is enormous thanks to its pipeline of promising drugs for treating central nervous system diseases. This chart shows how the market values intellectual capital: every employee, from scientists to managers, contributes to the creation of multi-billion-dollar value.
%20of%20the%20company%20Axsome%20Therapeutics%20(AXSM)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Axsome-Therapeutics-AXSM&v=1772567571020 "Chart of market capitalization per employee (in thousands of dollars) of the company Axsome Therapeutics (AXSM)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
Axsome Therapeutics is a biopharmaceutical company focused on diseases of the central nervous system (CNS). Like other biotechs, their primary assets are R&D and their patent portfolio. This chart shows the average market valuation per employee in their segment. It helps investors understand how much the market values their scientific potential and research team compared to the industry average.
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772567571144 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
Axsome Therapeutics develops innovative treatments for diseases of the central nervous system. The company's value is determined by its development portfolio and patents, not its staff. This chart illustrates the enormous value the market places on each employee, expecting their intellectual capital to yield breakthrough solutions in neuroscience.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772567571169 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Axsome Therapeutics (AXSM)
Axsome Therapeutics specializes in treating central nervous system diseases—an extremely complex and research-intensive field. For such a company, this chart is a measure of R&D effectiveness. It demonstrates how successfully investments in each researcher and specialist translate into the commercial success of drugs, where post-approval margins can be enormous.
%20Chart%20Axsome%20Therapeutics%20(AXSM)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Axsome-Therapeutics-AXSM&v=1772567571233 "Company Profit Per Employee (in thousands of dollars) Chart Axsome Therapeutics (AXSM)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
Axsome Therapeutics is a biopharmaceutical company focused on treating diseases of the central nervous system (neuro). This chart shows the benchmark for the "Neuro" (specialty pharmaceuticals) segment. In this industry, average profit per employee is traditionally high. It's a "patent business." A single successful drug, protected from competition, generates billions, more than covering the cost of its scientists and marketers. This benchmark shows the profitability of R&D.
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772567571327 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
Axsome Therapeutics (AXSM) is a biopharmaceutical company specializing in developing treatments for central nervous system (CNS) disorders such as depression and migraine. This chart, showing average earnings per employee across the market, serves as a backdrop. It helps assess how biotechnology, where a single successful drug can recoup years of R&D, is a high-margin industry in terms of intellectual capital.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772567571388 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Axsome Therapeutics (AXSM)
Axsome Therapeutics specializes in treating diseases of the central nervous system. For such an innovative company, this chart reflects the commercial potential of its research and development. High revenue per employee indicates that a small but highly qualified team has successfully brought a sought-after drug to market.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Axsome-Therapeutics-AXSM&v=1772567571463 "Sales chart per company employee Axsome Therapeutics (AXSM)")
Sales per employee in the market segment - Neuro
Axsome Therapeutics develops drugs for the treatment of central nervous system disorders. This is a high-barrier, expensive research area. Once approval is achieved, the efficiency of the commercial structure becomes crucial. This chart shows the average revenue per employee in the industry. It allows one to assess how successfully Axsome monetizes its scientific breakthroughs using its own staff compared to its competitors.
Sales per employee for the market as a whole
Axsome Therapeutics is bringing new drugs to market for the treatment of central nervous system disorders. Success here depends not only on discoveries but also on an effective commercial pipeline. How productive is their sales team? The dynamics of this graph provide the answer, illustrating the revenue the company can generate per employee, from scientists to marketers.
Short shares by company, segment and market as a whole
Shares shorted by company Axsome Therapeutics (AXSM)
Axsome Therapeutics specializes in treating central nervous system disorders such as depression and migraines. Despite recent success in drug approvals, the company faces intense competition. The chart demonstrates market skepticism: how many investors expect sales to fall short of lofty expectations or that drug candidates will fail to reach market.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Axsome-Therapeutics-AXSM&v=1772567571624 "Short Shares Chart for the Company Axsome Therapeutics (AXSM)")
Shares shorted by market segment - Neuro
Axsome Therapeutics focuses on treating diseases of the central nervous system, one of the most complex areas in medicine. This chart reflects the total volume of short positions across the entire segment. It indicates the overall confidence or lack of confidence investors have in the industry. A rising figure often signals general skepticism about an entire group of companies.
Shares shorted by the overall market
Axsome Therapeutics (AXSM) is a biotech company specializing in central nervous system disorders. Even with approved drugs, it is still perceived as a growth stock. A rise in Short_All signals an impending correction, during which investors dump growth stocks, regardless of sector, amid a general wave of pessimism.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Axsome Therapeutics (AXSM)
Axsome Therapeutics focuses on drugs for the treatment of central nervous system diseases. Success depends on drug approval and sales. This chart for AXSM can soar above 70 on positive FDA news or strong sales. A range below 30 is often associated with trial failures, delays, or competitive concerns.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Axsome-Therapeutics-AXSM&v=1772567571832 "RSI 14 indicator chart for the company's stock Axsome Therapeutics (AXSM)")
RSI 14 Market Segment - Neuro
Axsome Therapeutics (AXSM) is a biotech company specializing in central nervous system (CNS) disorders, such as depression and migraine. They strive to quickly bring new treatments to market. This chart measures the pulse of the Neuroscience segment. It helps distinguish the success of specific AXSM drugs from the overall "overheating" or "overselling" of the entire CNS biotech sector.
RSI 14 for the overall market
Axsome Therapeutics is a biotech company specializing in drugs for the treatment of central nervous system (CNS) disorders. Its success depends on regulatory approval. This chart shows the overall risk appetite in biotech. In times of panic, investors tend to sell off shares of companies whose revenue depends on future events rather than current sales.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast AXSM (Axsome Therapeutics)
Axsome Therapeutics (AXSM) is a biopharmaceutical company specializing in the treatment of central nervous system (CNS) disorders, such as depression and migraine. The chart displays the average Wall Street price target. It reflects analysts' assessments of the commercial success of Axsome's currently approved drugs and the potential of its future pipeline.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-AXSM-Axsome-Therapeutics&v=1772567571977 "A chart showing analyst consensus forecasts for the expected stock price. AXSM (Axsome Therapeutics)")
The difference between the consensus estimate and the actual stock price AXSM (Axsome Therapeutics)
Axsome Therapeutics is a biopharmaceutical company focused on CNS disorders (depression, migraine). This chart shows the difference between the consensus estimate and the price. It reflects whether analysts believe in the commercial success of its approved drugs and the potential of its R&D pipeline, seeing potential in them.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-AXSM-Axsome-Therapeutics&v=1772567572162 "A chart showing the difference between the consensus forecast and the actual stock price. AXSM (Axsome Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Neuro
Axsome Therapeutics is a biopharmaceutical company focused on central nervous system (CNS) diseases such as depression, migraine, and narcolepsy. This chart shows analysts' overall expectations for the neuroscience sector. It reflects whether experts believe new blockbuster drugs will emerge to treat brain diseases.
Analysts' consensus forecast for the overall market share price
Axsome Therapeutics (AXSM) is a biotech company focused on drugs for the treatment of central nervous system disorders (depression, migraine). This chart of overall market sentiment is important for biotech. Market optimism equals easy access to capital to fund expensive R&D and clinical trials. In times of crisis, investors may prefer boring pharma.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Axsome Therapeutics
Axsome Therapeutics is a biotech company focused on central nervous system (CNS) diseases. They have achieved success by commercializing drugs for depression and migraines. This chart evaluates their commercial success. It reflects the sales growth rate of their approved drugs and market expectations for their R&D pipeline in complex areas of psychiatry.
AKIMA Market Segment Index - Neuro
Axsome (AXSM) is a CNS (Central Nervous System) biotech focused on developing and commercializing new drugs for the treatment of depression and migraine. This summary metric evaluates R&D. The graph shows the average value for the segment. This benchmark: how does Axsome's CNS R&D focus differentiate it from the average pharma company?
The AKIM Index for the overall market
Axsome is a biotech company focused on the central nervous system (CNS). It develops and markets medications for depression and migraines. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this innovative scientific story, driven by the laws of biotech, compares to overall economic trends.
